Camidanlumab is a monoclonal antibody targeting CD25, which is expressed on activated T cells. Camidanlumab can be used in the synthesis of ADC Camidanlumab tesirine, which is investigated for the treatment of lymphoma and leukemia.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.